Global Neuropathic Pain Market Research Report Forecast to 2023

Global Neuropathic Pain Market Research Report Forecast to 2023

ID: MRFR/Pharma/0881-HCRR | July, 2017 | Region: Global | 85 pages | Half-Cooked Research Reports

Global Neuropathic Pain Market Research Report, by Drug Types (anticonvulsants, antidepressant, anaesthesia, steroids and other), by condition (peripheral neuropathy, diabetic neuropathy and other), by End User (retail pharmacies, hospitals and other) - Forecast Till 2023


Study Objectives Global Neuropathic Pain Market



  • Detail information about factors affecting the growth of the global neuropathic pain

  • Detail analysis of parent market with respect to all possible segmentation of the  

  • Detail analysis of emerging key players in the market along with effective strategies followed by them.

  • Detail Information about present market growth and forecasted market growth plus factors that influences the market growth on the global scale.

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments in the global neuropathic pain market.

  • Analysis of the market based on various analyses which includes price analysis, supply chain analysis, Porters Five Force analysis etc.

  • Detail information on the possible segments and sub segments of the market. Along with this regional analysis of the market which includes - North America, Europe, Asia Pacific plus Middle East and Africa.

  • Insights on major regions in which this market is blooming and to identify regions which are still untapped.

  • Detail information on trends followed and opportunities that are in various regions.


Intended Audience



  • Pharmaceutical companies

  • Research and development (R&D) companies

  • Government and independent research laboratories

  • Contract research organizations (CROs)

  • Medical research laboratories

  • Academic medical institutes and universities


Figure 1- Global Neuropathic Pain Market Share, by Condition

Neuropathic Pain Market Share, by Condition


 


Market Scenario:


Neuropathic pain is a chronic pain that occurs due to tissue injury and is associated with sensor motor system. The major driving factor for global neuropathy pain market is increasing prevalence of diseases like cancer and diabetes. These two diseases are major cause for neuropathy pain. According to the latest study, 16 % of global population is suffering from painful diabetic neuropathy. Beside this increase in the demand for generic drugs and rapid launch of new neuropathic drug in the market has provided fuel for the growth of this market. On the other hand increasing side effects of steroids and increasing cost of branded drugs may hamper the growth of this market.


Global neuropathic pain market was $ 5.5 billion in 2017 and is expected to reach to $ 8.1 billion by growing at the CAGR of 5.5% during forecasted period of 2017-2023.


Segmentation


The market is segmented into following which includes by drug types (anticonvulsants, antidepressant, anaesthesia, steroids and other), by condition (Peripheral neuropathy, diabetic neuropathy and other) and by end user (retail pharmacies, hospitals and other)


Regional Analysis


On regional basis, North America dominates the neuropathic pain market. Due to increase in number of diseases like diabetes and cancer in this region, all these have developed the market in North America. Beside this increasing aging population in this region has also provided a push to the market’s growth. In neuropathic pain market North America is followed by Europe. Improved infrastructure, increase in technological advance and prevalence of diseases which causes neuropathic pain has led to the growth of this market in Europe.


Asia Pacific is a developing region. Due to a huge demand of advance treatment for neuropathic pain along with increase in prevalence of diabetes in this region all these will allow growth of this market by the CAGR of 6.4% during the forecasted period.


Key Players in the global Neuropathic Pain Market


Some of the key players in this market are Pfizer Inc., Depomed Inc., Johnson & Johnson Services Inc., Eli Lily and Company, GlaxoSmithKline PLC, Bristol-Myers Squibb and Company, Sanofi S.A, Baxter Healthcare Corporation, and Biogen Idec Inc.


Market Assessment

Market Assessment Neuropathic Pain Market

The report of global neuropathic pain market by Market Research Future comprises of extensive primary research along with detail analysis of qualitative as well as quantitative aspects by various industry experts and key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the market’s segments and regions.

 

1          INTRODUCTION           

1.1        DEFINITION     

1.2        SCOPE OF STUDY      

1.2.1     RESEARCH OBJECTIVE          

1.2.2     ASSUMPTIONS & LIMITATIONS

1.2.2.1  ASSUMPTIONS

1.2.2.2  LIMITATIONS    

1.3        MARKET STRUCTURE:

2          RESEARCH METHODOLOGY   

2.1        RESEARCH PROCESS:           

2.2        PRIMARY RESEARCH 

2.3        SECONDARY RESEARCH:      

3          MARKET DYNAMICS   

3.1        DRIVERS         

3.2        RESTRAINTS               

3.3        OPPORTUNITIES         

3.4        MACROECONOMIC INDICATORS         

4          MARKET FACTOR ANALYSIS   

4.1        PORTERS FIVE FORCES MODEL        

4.2        BARGAINING POWER OF SUPPLIERS 

4.3        BARGAINING POWER OF BUYERS      

4.4        THREAT OF NEW ENTRANTS   

4.5        THREAT OF SUBSTITUTES      

4.6        INTENSITY OF RIVALRY           

5.         GLOBAL NEUROPATHIC PAIN MARKET, BY DRUG TYPE

5.1        ANTICONVULSANTS

5.2        ANTIDEPRESSANT

5.3        ANAESTHESIA

5.4        STEROIDS

5.5        OTHER

6.         GLOBAL NEUROPATHIC PAIN MARKET, BY DISEASE CAUSE

6.1        PERIPHERAL NEUROPATHY

6.2        DIABETIC NEUROPATHY

6.3        OTHER

7.         GLOBAL NEUROPATHIC PAIN MARKET, BY END USER

7.1        RETAIL PHARMACIES

7.2        HOSPITALS

7.3        OTHER

8.         GLOBAL PAIN MANAGEMENT DEVICES MARKET, BY REGION

8.1        INTRODUCTION

8.2        NORTH AMERICA

8.2.1     US

8.2.2     CANADA

8.3        EUROPE

8.3.1     WESTERN EUROPE

8.3.1.1  GERMANY

8.3.1.2  FRANCE

8.3.1.3  ITALY

8.3.1.3  SPAIN

8.3.1.5  UK

8.3.1.6  REST OF WESTERN EUROPE

8.3.2     EASTERN EUROPE

8.4        ASIA

8.4.1     JAPAN

8.4.2     CHINA

8.4.3     INDIA

8.4.4     AUSTRALIA

8.4.5     REPUBLIC OF KOREA

8.5        REST OF ASIA-PACIFIC

8.6        MIDDLE EAST & AFRICA

9.         COMPETITIVE LANDSCAPE     

9.1        MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS         

9.1.1     STRATEGIC PARTNERSHIP     

9.1.2     MERGER & ACQUISITION        

10         COMPANY PROFILE    

10.1      PFIZER INC.

10.1.1   OVERVIEW      

10.1.2   PRODUCT OVERVIEW 

10.1.3   FINANCIALS    

10.1.4   KEY DEVELOPMENTS

10.2      DEPOMED INC.

10.2.1   OVERVIEW      

10.2.2   PRODUCT OVERVIEW 

10.2.3   FINANCIALS    

10.2.4   KEY DEVELOPMENTS

10.3      ELI LILY AND COMPANY

10.3.1   OVERVIEW

10.3.2   PRODUCT OVERVIEW 

10.3.3   FINANCIALS

10.3.4   STRATEGY      

10.3.5   KEY DEVELOPMENT   

10.4      GLAXOSMITHKLINE PLC

10.4.1   OVERVIEW

10.4.2   PRODUCT OVERVIEW

10.4.3   FINANCIALS

10.4.4   KEY DEVELOPMENTS

10.5      BIOGEN IDEC INC

10.5.1   OVERVIEW

10.5.2   PRODUCT OVERVIEW 

10.5.3   FINANCIALS    

10.5.4   KEY DEVELOPMENTS

10.6      OTHERS